Sometimes, and it depends far more on who designed your plan than on the medication itself. Coverage for weight-management drugs is an optional benefit, so two people carrying cards from the same insurance company can get opposite answers. If you have already been denied, you almost always have a formal appeal right with fixed deadlines. And if the appeal does not go your way, several cash-pay routes remain, including compounded semaglutide through telos rx at $99 a month.
This guide walks through how coverage decisions are actually made, why denials happen, what an appeal typically involves, and what your realistic options are if the answer stays no. Wegovy is a registered trademark of Novo Nordisk. telos rx is not affiliated with Novo Nordisk and does not sell or supply Wegovy.
There is no national answer to "is Wegovy covered by insurance." Coverage turns on three separate questions. Does your plan cover weight-management drugs at all? Is Wegovy on that plan's drug list? Do you meet the plan's own clinical criteria? A no on any one of the three produces a denial.
The only reliable source is your own plan documents and the number on the back of your card. Everything below is how the machinery generally works, not a prediction about your plan.
Why coverage varies so much from person to person
Health plans divide medications into categories, and weight-management drugs sit in an unusual one. Unlike, say, insulin or antibiotics, drugs prescribed for chronic weight management are frequently treated as an add-on benefit that an employer or plan sponsor chooses to buy, or chooses to leave out.
That choice is where most of the variation comes from. According to the KFF 2025 Employer Health Benefits Survey, 67 percent of covered workers are in self-funded plans. In those plans the employer pays claims from its own money and the insurance company is largely an administrator. So the employer decides whether weight-management drugs are covered, not the carrier whose logo is on your card.
The same survey found coverage of GLP-1 medications for weight loss varies sharply by employer size. In 2025 it was offered in the largest plan of 16 percent of firms with 200 to 999 workers, 30 percent of firms with 1,000 to 4,999 workers, and 43 percent of firms with 5,000 or more. Those numbers also move year to year as employers respond to cost.
Key takeaway: "Does UnitedHealthcare cover Wegovy" and "does Blue Cross Blue Shield cover Wegovy" are not answerable questions. Those are not single plans. Blue Cross Blue Shield in particular is a federation of independent local companies, and every large carrier administers thousands of separate employer plan designs. Your neighbor can be covered and you can be excluded on cards that look identical.
How to check your own coverage properly
Skip the forums. Go straight to the two sources that actually govern your plan.
1. Call the member services number on the back of your card and ask about the pharmacy benefit specifically, not the medical benefit. Weight-management drugs almost always sit under the pharmacy side.
2. Ask for these exact things:
- Is Wegovy on my plan's formulary, and on which tier?
- Does my plan cover any medication for chronic weight management, or is that category excluded entirely?
- If it is covered, does it require prior authorization, and can you send me the criteria document?
- Is there a step therapy requirement, and which medications must be tried first?
- Are there quantity limits or a duration limit?
- What would my copay or coinsurance be at each dose?
3. Get it in writing. Ask for the reference number for the call and request the prior authorization criteria by email or mail. That document is the single most useful thing you can hand your prescriber, because it tells them exactly what to document.
Your pharmacy benefit may be administered by a pharmacy benefit manager rather than the carrier itself. Names like CVS Caremark, Express Scripts and Optum Rx publish general formulary and exclusion documents, and those documents are a reasonable place to start reading. Treat them as a starting point only. Employers routinely customize the standard list, so a drug's presence or absence on a published national formulary does not settle what your plan does. Novo Nordisk also publishes a coverage lookup tool on its own Wegovy site, which can be a quick first check before you call.
The five reasons Wegovy claims typically get denied
Denial letters are written in benefits language that does not always make the underlying reason obvious. Here is how the common ones usually translate.
Note the important split in that table. A prior authorization denial and a benefit exclusion feel identical when you are standing at the pharmacy counter, but they lead to completely different next steps. Identify which one you have before spending energy on an appeal.
Where BMI criteria come from
Most plan criteria are built on the medication's approved labeling. According to the FDA-approved prescribing information, Wegovy is indicated alongside a reduced-calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction. That applies to adults with obesity, and to adults with overweight who also have at least one weight-related condition. The same label defines obesity as a BMI of 30 or above, and overweight as a BMI of 27 to 29.9. It also carries indications relating to cardiovascular risk reduction and to a specific liver condition.
Plans typically turn that into a checklist. A documented BMI at or above a threshold. A named weight-related condition if the BMI falls in the overweight range. Evidence of a supervised diet and exercise attempt. Sometimes baseline labs. Some plans add requirements on top, such as documented participation in a lifestyle program for a set number of months, or proof of weight loss to continue coverage.
If your denial cites medical necessity, ask for the criteria list and go through it point by point with your prescriber. Denials at this stage are frequently a documentation problem rather than a clinical disagreement.
Medicare, Medicaid and marketplace plans
These sit under different rules again, and they change, so verify rather than assume.
Medicare Part D has historically been barred by statute from covering drugs used for weight loss. That is why weight-management medication was unavailable to most Medicare beneficiaries for years. The picture has shifted as products gained approved indications beyond weight loss, but individual Part D plans still control their own formularies, tiering and prior authorization. Novo Nordisk's own Wegovy site also describes a Medicare GLP-1 Bridge arrangement at $50 per month for eligible Part D beneficiaries beginning July 1, 2026. If you are on Medicare, call your Part D plan and ask what applies to you specifically.
Medicaid coverage of weight-management drugs is set state by state and varies widely. Marketplace and individual plans set their own formularies too. In every one of these cases the answer lives in your plan's own documents, not in a general article.
How an appeal actually works
This is the part most people skip, and it is the part with real leverage. Federal rules give people in most plans a structured appeal process with enforceable deadlines. The details below come from HealthCare.gov's published guidance on internal appeals and external review. Your specific plan may have its own variations, and its denial notice must tell you how to proceed.
Stage one: the internal appeal
Your insurer has to tell you in writing why a claim was denied. That notice is generally due within 15 days when you are seeking prior authorization, 30 days for services already received, and 72 hours for urgent care cases.
You then have 180 days, six months, from receiving that denial notice to file an internal appeal. Complete the insurer's forms, or write in with your name, claim number and insurance ID number. Attach anything you want considered, such as a letter from your doctor. Your state's Consumer Assistance Program can also file the appeal for you.
The internal appeal must be completed within 30 days if it concerns a service you have not yet received, and within 60 days for a service already provided. You get a written decision at the end.
Stage two: independent external review
If the internal appeal is denied, you can request an external review, which is decided by a reviewer outside the insurance company. You have four months from the final determination to file a written request. Standard external reviews are decided no later than 45 days after the request is received. Expedited reviews are decided no later than 72 hours, or sooner depending on medical urgency.
The important part: the insurer is required by law to accept the external reviewer's decision. If the HHS-administered federal process applies, there is no charge, and where an issuer contracts with an independent review organization or a state process applies, the charge cannot exceed $25. You may appoint a representative, such as your doctor, to file on your behalf.
Urgent cases
If waiting for the standard timeline would seriously jeopardize your life or your ability to regain maximum function, you can file an expedited appeal. In that case you may file the internal appeal and the external review request at the same time. A final decision must come as quickly as your condition requires, and at least within four business days of the request.
What to put in the file:
- The denial letter and the Explanation of Benefits
- The plan's own prior authorization criteria document
- A letter of medical necessity that answers each criterion in order
- Chart notes documenting BMI and any weight-related conditions
- Records of previous weight-management attempts
- Documentation of any preferred medication you tried and could not tolerate
Keep copies of everything, and log the date, time and name of every person you speak to. Nobody can tell you an appeal will succeed. What is true is that the process exists, the deadlines are enforceable, and a well-documented file has the best chance of being read properly.
An appeal is also not the only lever. If your denial is a straight benefit exclusion, the decision-maker is your employer, not your insurer. Novo Nordisk publishes a sample letter for employees to send to their HR department requesting that coverage be added. Open enrollment is the point in the year when plan design actually gets revisited.
What Wegovy costs if you pay for it yourself
If coverage is not going to happen, it helps to know the manufacturer's published numbers rather than guess. The figures below are taken from Novo Nordisk's own NovoCare and Wegovy pages as of publication in September 2026. Manufacturer prices and savings terms change frequently, so verify current pricing on the manufacturer's site before you rely on any of it.
- List price: $1,349.02 per package, published on NovoCare for all formulations. Very few people pay this, but it is the number the rest of the system discounts from.
- With commercial insurance that covers Wegovy: the Wegovy Savings Offer is advertised as "pay as little as $25 per month", subject to a maximum saving of $100 per month. Government beneficiaries are excluded unless they pay outside their insurance.
- Self-pay through NovoCare Pharmacy, injection pen: $349 per month for the 0.25 mg through 2.4 mg doses, and $399 per month for the 7.2 mg high-dose pen.
- Introductory self-pay offer: $199 per month for the first two monthly fills of 0.25 mg and 0.5 mg for patients new to the offer, stated as running through December 31, 2026.
- Self-pay, oral tablet: from $149 per month at 1.5 mg, with higher prices at higher doses.
- Medicare: $50 per month under the Medicare GLP-1 Bridge arrangement for eligible Part D beneficiaries, described as starting July 1, 2026.
Two things worth knowing about savings cards generally. Money spent through a manufacturer savings offer usually does not count toward your deductible or out-of-pocket maximum and cannot be submitted to your insurer for reimbursement. And savings offers typically exclude people with government insurance. Read the terms rather than assuming you qualify.
Your realistic options if the answer is no
Best when the denial is about prior authorization, medical necessity, step therapy or quantity limits. Deadlines are fixed, so act promptly.
Worth checking if you have commercial insurance. Terms, caps and exclusions apply, and government beneficiaries are generally excluded.
Novo Nordisk sells Wegovy direct to self-pay patients through NovoCare Pharmacy at published rates. This is the route to brand-name Wegovy without insurance.
Ask which weight-management or metabolic medications your plan does cover. Sometimes a covered option exists that nobody mentioned.
A separate, insurance-free path. Compounded semaglutide from $99 a month, subject to provider approval. Not FDA-approved, and not the same product as Wegovy.
Where telos rx fits, and what it is not
telos rx is an online-first, LegitScript-certified telehealth service. It does not bill insurance, accept insurance, or handle prior authorizations. It is a cash-pay option, which is precisely why it is relevant to people whose plans exclude this category of medication: there is no coverage decision to lose.
Being direct about what this is matters more than the price. Compounded semaglutide is a preparation made by a licensed compounding pharmacy against an individual prescription. It contains the same active ingredient as Wegovy, semaglutide, but it is a different product. It is not a generic version of Wegovy, and no generic Wegovy exists. It is not an equivalent, a substitute or a copy. Compounded medications are not FDA-approved and have not been reviewed by the FDA for safety, effectiveness or quality. Whether it is appropriate for you is a decision for a licensed clinician, and approval is never guaranteed.
What is included at $99 a month, verified on the live product page as of publication:
- Compounded semaglutide dispensed by a licensed US compounding pharmacy, with free 2-day shipping if approved
- Flat pricing that does not change as a clinician titrates your dose
- Quarterly labs and unlimited messaging with the care team
- FSA and HSA eligible, which can matter a great deal when insurance will not pay
- Cancel in one click, no penalty and no retention call
- A full refund if a provider declines you, since charges are final only once a prescription reaches the pharmacy
Prescriptions are reviewed by clinicians at Arora Health Group and dispensed by VialsRX and Jungle Jim's. Compounded tirzepatide is also available from $139 a month if that molecule is a better fit for you. If you are weighing the numbers, our semaglutide cost guide and our breakdown of tirzepatide without insurance go deeper on cash pricing.
GLP-1 medications are not right for everyone. Providers screen for issues including a personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, pancreatitis and pregnancy. Side effects can include nausea and other digestive changes, particularly early on. Share your full history at intake.
Frequently asked questions
Does insurance cover Wegovy?
Some plans do and many do not. Coverage of weight-management medication is generally an optional benefit chosen by an employer or plan sponsor, so it varies by plan rather than by insurance company. Check your own plan's formulary and prior authorization criteria, and call the member services number on your card. No article can tell you whether your specific plan covers it.
Why was my Wegovy prior authorization denied?
There are five common reasons. A formulary exclusion or benefit carve-out. Missing or incomplete prior authorization paperwork. Documentation that did not meet the plan's medical necessity criteria, such as BMI or a qualifying weight-related condition. A step therapy requirement to try a preferred medication first. Or a quantity limit. Your denial notice must state the reason, and that determines what to do next.
How do I get insurance to cover Wegovy?
Request the plan's prior authorization criteria in writing and give them to your prescriber, so the submission answers each requirement directly. If you are denied, you generally have 180 days to file an internal appeal. From a final denial you then have four months to request an independent external review, and the insurer is legally required to accept that reviewer's decision. If the denial is a benefit exclusion rather than a clinical one, the conversation is with your employer at open enrollment. No process guarantees an outcome.
Does Medicare cover Wegovy?
Medicare Part D has historically been prohibited by statute from covering drugs used for weight loss. The picture has shifted as products gained approved indications beyond weight loss, but each Part D plan still sets its own formulary and restrictions. Novo Nordisk also describes a Medicare GLP-1 Bridge arrangement at $50 per month for eligible Part D beneficiaries beginning July 1, 2026. Call your Part D plan to confirm what applies to you.
How much does Wegovy cost without insurance?
Novo Nordisk publishes self-pay pricing through NovoCare Pharmacy. As of publication in September 2026 that is $349 per month for the 0.25 mg to 2.4 mg pens and $399 per month for the 7.2 mg pen. New patients are offered an introductory rate of $199 per month for the first two fills through December 31, 2026, and oral tablet pricing starts at $149 per month. The published list price is $1,349.02 per package. Verify current pricing with the manufacturer.
Is compounded semaglutide the same as Wegovy?
No. Compounded semaglutide contains the same active ingredient but it is a different, compounded preparation made by a licensed pharmacy against an individual prescription. It is not a generic, an equivalent or a substitute for Wegovy, there is no generic Wegovy, and compounded medications are not FDA-approved and have not been reviewed by the FDA for safety, effectiveness or quality. Whether it is appropriate is a decision for a licensed clinician.
Appeal first if you have grounds. If your plan simply does not buy this category, cash-pay care removes the coverage question entirely. See every option and price on the telos rx GLP-1 options page, or start an online visit and let a licensed provider decide whether treatment is appropriate for you.
Start your online visit →Wegovy, Ozempic, Zepbound and Mounjaro are registered trademarks of their respective owners. TelosRX is not affiliated with, endorsed by, or sponsored by Novo Nordisk or Eli Lilly, and does not sell, supply or dispense those products. Manufacturer prices, savings-offer terms and plan formularies change frequently; every figure above is stated as of publication and should be verified at the source. This article is general information about how coverage and appeals processes typically work. It is not medical, insurance or legal advice.
TelosRX is LegitScript-certified. Compounded medications are not FDA-approved and have not been reviewed by the FDA for safety, effectiveness or quality. They are prepared under federal compounding regulations. Approval is subject to evaluation by a licensed provider; approval is not guaranteed. Individual results vary. TelosRX operates as an online-first, asynchronous telehealth service.
Start your private evaluation at telos rx.